This work describes the replacement of Tissue Phantom Ratio (TPR) measurements with beam profile flatness measurements to determine photon beam quality during routine quality assurance (QA) measurements. To achieve this, a relationship was derived between the existing TPR15/5 energy metric and beam flatness, to provide baseline values and clinically relevant tolerances. The beam quality was varied around two nominal beam energy values for four matched Elekta linear accelerators (linacs) by varying the bending magnet currents and reoptimizing the beam. For each adjusted beam quality the TPR15/5 was measured using an ionization chamber and Solid Water phantom. Two metrics of beam flatness were evaluated using two identical commercial ionization chamber arrays. A linear relationship was found between TPR15/5 and both metrics of flatness, for both nominal energies and on all linacs. Baseline diagonal flatness (FDN) values were measured to be 103.0% (ranging from 102.5% to 103.8%) for 6 MV and 102.7% (ranging from 102.6% to 102.8%) for 10 MV across all four linacs. Clinically acceptable tolerances of ±2% for 6 MV, and ±2% for 10 MV, were derived to equate to the current TPR15/5 clinical tolerance of ±0.5%. Small variations in the baseline diagonal flatness values were observed between ionization chamber arrays; however, the rate of change of TPR15/5 with diagonal flatness was found to remain within experimental uncertainty. Measurements of beam flatness were shown to display an increased sensitivity to variations in the beam quality when compared to TPR measurements. This effect is amplified for higher nominal energy photons. The derivation of clinical baselines and associated tolerances has allowed this method to be incorporated into routine QA, streamlining the process whilst also increasing versatility. In addition, the effect of beam adjustment can be observed in real time, allowing increased practicality during corrective and preventive maintenance interventions.PACS number: 87.56.Fc
Abstract. This paper describes the design and prototype implementation of a novel architecture for integrated concept, metadata and content based browsing and retrieval of museum information. The work is part of a European project involving several major galleries and the aim is to provide more versatile access to digital collections of museum artefacts, including 2-D images, 3-D models and other multimedia representations. An ontology for the museum domain, based on the CIDOC Conceptual Reference Model, is being developed as a semantic layer with references to the digital collection as instance information. A graphical concept browser is an integral component in the user interface, allowing navigation through the semantic layer, display of thumbnails, or full representations of artefacts and textual information in appropriate viewers and the invocation of conventional content based searching or combined querying. Semantic Web technologies are used in system integration to describe how tools for analysis and visualisation can be applied to different data types and sources. This supports flexible and managed formulation, execution and interpretation of the results of distributed multimedia queries. Combined searches using concepts, content and metadata can be initiated from a single user interface.
Abstract. The paper describes the prototype design and development of a multimedia system for museums and galleries. Key elements in the system are the introduction of 3-D models of museum artefacts together with 3-D as well as 2-D content based retrieval and navigation facilities and the development of a semantic layer, centred on an ontology for museums, which aims to expose the richness of knowledge associated with the museum collections and facilitate concept based retrieval and navigation integrated with that based on content and metadata. Interoperability protocols are designed to allow external applications to access the collection and an example is given of an e-Learning facility which uses models extracted to a virtual museum.
Monte Carlo (MC)-based treatment planning requires a choice of dose voxel size (DVS) and statistical uncertainty (SU). These parameters effect both the precision of displayed dose distribution and time taken to complete a calculation. For efficient, accurate, and precise treatment planning in a clinical setting, optimal values should be selected. In this investigation, 30 volumetric modulated arc therapy (VMAT) stereotactic radiotherapy (SRT) treatment plans, 10 brain, 10 lung, and 10 spine were calculated in the Monaco 5.11.02 treatment planning system (TPS). Each plan was calculated with a DVS of 0.1 and 0.2 cm using SU values of 0.50%, 0.75%, 1.00%, 1.50%, and 2.00%, along with a ground truth calculation using a DVS of 0.1 cm and SU of 0.15%. The variance at each relative dose level was calculated for all SU settings to assess their relationship. The variation from the ground truth calculation for each DVS and SU combination was determined for a range of DVH metrics and plan quality indices along with the time taken to complete the calculations. Finally, the effect of defining the maximum dose using a volume of 0.035 cc was compared to 0.100 cc when considering DVS and SU settings. Changes in the DVS produced greater variations from the ground truth calculation than changes in SU across the values tested. Plan quality metrics and mean dose values showed less sensitivity to changes in SU than DVH metrics. From this study, it was concluded that while maintaining an average calculation time of <10 min, 75% of plans could be calculated with variations of <2.0% from their ground truth values when using an SU setting of 1.50% and a DVS of 0.1 cm in the case of brain or spine plans, and a 0.2 cm DVS in the case of lung plans.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.